| Mutant NPM1 maintains the leukemic state through HOX expression L Brunetti, MC Gundry, D Sorcini, AG Guzman, YH Huang, ... Cancer cell 34 (3), 499-512. e9, 2018 | 239 | 2018 |
| Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells MP Martelli, I Gionfriddo, F Mezzasoma, F Milano, S Pierangeli, F Mulas, ... Blood, The Journal of the American Society of Hematology 125 (22), 3455-3465, 2015 | 157 | 2015 |
| CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice MP Martelli, V Pettirossi, C Thiede, E Bonifacio, F Mezzasoma, D Cecchini, ... Blood, The Journal of the American Society of Hematology 116 (19), 3907-3922, 2010 | 137 | 2010 |
| Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML MP Martelli, R Rossi, A Venanzi, M Meggendorfer, VM Perriello, G Martino, ... Blood, The Journal of the American Society of Hematology 138 (25), 2696-2701, 2021 | 35 | 2021 |
| Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML I Gionfriddo, L Brunetti, F Mezzasoma, F Milano, V Cardinali, R Ranieri, ... Leukemia 35 (9), 2552-2562, 2021 | 28 | 2021 |
| Decreased NOTCH1 activation correlates with response to ibrutinib in chronic lymphocytic leukemia B Del Papa, S Baldoni, E Dorillo, F De Falco, C Rompietti, D Cecchini, ... Clinical Cancer Research 25 (24), 7540-7553, 2019 | 25 | 2019 |
| IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation F De Falco, B Del Papa, S Baldoni, R Sabatini, F Falzetti, M Di Ianni, ... Cell Death & Disease 9 (12), 1160, 2018 | 25 | 2018 |
| CD123 Is Consistently Expressed on NPM1-Mutated AML Cells VM Perriello, I Gionfriddo, R Rossi, F Milano, F Mezzasoma, A Marra, ... Cancers 13 (3), 496, 2021 | 21 | 2021 |
| Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML G Pianigiani, A Gagliardi, F Mezzasoma, F Rocchio, V Tini, B Bigerna, ... Blood Advances 6 (22), 5938-5949, 2022 | 12 | 2022 |
| Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. MP Martelli, V Pettirossi, N Manes, A Liso, F Mezzasoma, F Cecchetti, ... Blood 110 (11), 868, 2007 | 12 | 2007 |
| SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations G Spinozzi, V Tini, A Ferrari, I Gionfriddo, R Ranieri, F Milano, ... Biomolecules 12 (7), 904, 2022 | 9 | 2022 |
| IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML VM Perriello, MC Rotiroti, I Pisani, S Galimberti, G Alberti, G Pianigiani, ... Blood Advances 7 (12), 2855-2871, 2023 | 7 | 2023 |
| Tuned IL3-Zetakine coupled to a CD33 costimulatory receptor as a dual CAR for safer and selective targeting of acute myeloid leukemia VM Perriello, MC Rotiroti, I Pisani, S Galimberti, G Alberti, G Pianigiani, ... Blood 140 (Supplement 1), 10237-10238, 2022 | 1 | 2022 |
| Abstract P195: Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived … F Mezzasoma, V Cardinali, I Gionfriddo, F Milano, S Sciabolacci, A Ferrari, ... Molecular Cancer Therapeutics 20 (12_Supplement), P195-P195, 2021 | 1 | 2021 |
| Evidence for CD34+ hematopoietic progenitor cell involvement in acute myeloid leukemia with NPM1 gene mutation: implications for the cell of origin MP Martelli, V Pettirossi, E Bonifacio, F Mezzasoma, N Manes, D Cecchini, ... Blood 112 (11), 307, 2008 | 1 | 2008 |
| Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations MP Martelli, V Pettirossi, N Manes, F Susta, PL Orvietani, A Liso, ... HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008 | 1 | 2008 |
| Poster: AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma, Myeloma and Leukemia 22, S134, 2022 | | 2022 |
| AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma Myeloma and Leukemia 22, S242, 2022 | | 2022 |
| CORRECTION OF THE DNMT3A MUTATION IN OCI-AML3 HARBOURING DNMT3AR882C MUTATION AND NPM1 MUTATION A DOES NOT AFFECT LEUKEMIA SURVIVAL AND GROWTH IN VITRO AND IN VIVO F Milano, C Quadalti, LA Giovinati, S Pierangeli, M Sabino, R Ranieri, ... HAEMATOLOGICA 107, 17-18, 2022 | | 2022 |
| Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived xenograft (PDX) models to support a … F Mezzasoma, V Cardinali, I Gionfriddo, F Milano, S Sciabolacci, A Ferrari, ... MOLECULAR CANCER THERAPEUTICS 20 (12), 2021 | | 2021 |
